Saturday, October 3, 2026
ExploreSearch
Via News
MarketCommodities

Palladium Futures Bearish By 12% In The Last 21 Sessions

Palladium Futures Bearish By 12% In The Last 21 Sessions

(VIANEWS) - Palladium (PA) has been up by 12.7% for the last 21 sessions. At 07:52 EST on Friday, 3 March, Palladium (PA) is $1,430.00.

Volume

Today's last reported volume for Palladium is 476, 99.99% below its average volume of 5099299309.21.

Volatility

Palladium's last week, last month's, and last quarter's current intraday variation average was a negative 1.32%, a negative 0.16%, and a positive 2.25%, respectively.

Palladium's highest amplitude of average volatility was 2.41% (last week), 2.09% (last month), and 2.25% (last quarter), respectively.

Commodity Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Palladium's commodity is considered to be oversold (<=20).

News about

  • Crude oil forecast: continues to do very little as traders wait for momentum - 02 March 2023. According to DailyForex on Thursday, 2 March, "During Wednesday's trading session, the West Texas Intermediate Crude Oil market initially experienced a slight surge. "

More news about Palladium (PA).

Categories

MarketCommodities

Tags

CommodityCommoditiesFuturesPAPalladiumPrice DownCommodities Price DownCommodities Now
ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI-Driven Drug Development Meets Biotech Deal-Making and Regulatory Catalysts
AI-designed therapeutics (Insilico's rentosertib showing biological-age reductions) are moving into the clinical mainstream. Large-cap biotech is simultaneously reallocating capital through M&A (Lilly–Merida, $2.9B) and government funding (BARDA–Basilea), while trial failures (ziltivekimab, a 9.4% Novo Nordisk share drop) and upcoming FDA catalysts (the ivonescimab PDUFA on 2026-11-14) drive volatility. The wider AI regulatory and legal climate (Tesla Cybercab probe, xAI's Minnesota loss, OpenAI suits) is tightening, though QAIAx's micro-cap trial claims are speculative and weakly connected.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,327 source documents archived
Query this data → isubstrate.com